Johnson & Johnson also terminated a trial of its own tau-targeting antibody, posdinemab, in late 2025
Among emerging compounds, Pentadeca Arginate (PDA) 1 a next-generation peptide, has drawn interest for its potential to accelerate joint and muscle healing
Researchers have observed that BPC-157 interacts with the nitric oxide (NO) system, the dopamine system, and the prostaglandin pathway, suggesting a multi-targeted mechanism of action that goes beyond simple wound closure
Enhanced Recovery: Preclinical research suggests improved outcomes when combining regenerative compounds with different mechanisms
When BPC-157 stimulates tendon fibroblast cells, it dramatically increases phosphorylation of FAK and paxillin
However, the mechanism is specific, the dose-response is documented, and the target (ZO-1 restoration) is a validated therapeutic goal in IBD research